The company we keep: Why physicians should refuse to see pharmaceutical representatives

被引:42
作者
Brody, H
机构
[1] Michigan State Univ, Dept Family Practice, E Lansing, MI 48824 USA
[2] Michigan State Univ, Ctr Eth & Humanities Life Sci, E Lansing, MI 48824 USA
关键词
drug industry; ethics; health care delivery; health services research;
D O I
10.1370/afm.259
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Whether physicians ought to interact with pharmaceutical sales representatives (reps) is a question worthy of careful ethical analysis. The issue presents a challenge to both professional integrity and time management. Empirical data suggest that interactions with pharmaceutical reps increase the chances that the physician will act contrary to duties owed to the patient. Ideally, a physician might both interact with reps and also do the research necessary to counteract the commercial bias in their messages. But a physician who actually did that research would, in turn, be devoting a good deal of time that might better be spent in other activities. The counter-argument, that one is obligated to see representatives to obtain free samples to best serve one's patients, can be shown in most practice settings not to be compelling. Physicians ought to refuse to visit with representatives as a matter of both professional integrity and sensible time management.
引用
收藏
页码:82 / 85
页数:4
相关论文
共 24 条